Comparing Ariad Pharmaceuticals (NASDAQ:ARIA) and Cascadian Therapeutics (CASC)

Cascadian Therapeutics (NASDAQ: CASC) and Ariad Pharmaceuticals (NASDAQ:ARIA) are both companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.

Earnings & Valuation

How to Become a New Pot Stock Millionaire

This table compares Cascadian Therapeutics and Ariad Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cascadian Therapeutics N/A N/A -$56.93 million N/A N/A
Ariad Pharmaceuticals N/A N/A N/A N/A N/A

Insider & Institutional Ownership

81.4% of Cascadian Therapeutics shares are held by institutional investors. Comparatively, 87.0% of Ariad Pharmaceuticals shares are held by institutional investors. 1.1% of Cascadian Therapeutics shares are held by company insiders. Comparatively, 8.2% of Ariad Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


This table compares Cascadian Therapeutics and Ariad Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cascadian Therapeutics N/A -43.53% -40.90%
Ariad Pharmaceuticals -60.47% N/A -17.16%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Cascadian Therapeutics and Ariad Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cascadian Therapeutics 1 2 2 0 2.20
Ariad Pharmaceuticals 0 0 0 0 N/A

Cascadian Therapeutics currently has a consensus target price of $7.00, indicating a potential downside of 29.86%. Given Cascadian Therapeutics’ higher possible upside, equities analysts clearly believe Cascadian Therapeutics is more favorable than Ariad Pharmaceuticals.


Ariad Pharmaceuticals beats Cascadian Therapeutics on 4 of the 7 factors compared between the two stocks.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company’s ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

About Ariad Pharmaceuticals

ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply